Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
About Compass Therapeutics Inc.
Compass Therapeutics Inc. (Nasdaq: CMPX) is a clinical-stage oncology-focused biopharmaceutical company dedicated to developing innovative antibody-based therapeutics to treat a range of cancers and other human diseases. Headquartered in Boston, Massachusetts, Compass leverages cutting-edge science to address the intricate relationship between angiogenesis, the immune system, and tumor growth. The company’s mission is to deliver transformative therapies that target critical biological pathways, enabling more effective anti-tumor responses.
Core Focus and Proprietary Platforms
Compass Therapeutics is at the forefront of antibody discovery and development, with a focus on bispecific antibodies, monoclonal antibodies, and engineered protein constructs. The company’s proprietary platforms, including StitchMabs and common light chain technologies, empower researchers to empirically identify optimal drug combinations. This approach allows for rapid translation of preclinical insights into tailored therapeutics with monoclonal-like manufacturability, positioning Compass as a leader in the field of combinatorial immunotherapy.
Pipeline and Clinical Programs
Compass Therapeutics boasts a robust pipeline targeting multiple critical pathways involved in tumor progression and immune evasion:
- Tovecimig (CTX-009): A bispecific antibody targeting DLL4 and VEGF-A, designed to inhibit angiogenesis and tumor vascularization. Currently in Phase 2/3 clinical trials for advanced biliary tract cancers (BTC) and being evaluated for additional indications like colorectal cancer (CRC).
- CTX-471: A novel CD137 agonist antibody that activates immune effector cells within the tumor microenvironment. Early clinical results suggest potential efficacy in melanoma, small-cell lung cancer, and mesothelioma, with biomarker-driven Phase 2 trials planned.
- CTX-8371: A next-generation bispecific checkpoint inhibitor targeting PD-1 and PD-L1, with a unique mechanism involving proteolytic cleavage of cell surface PD-1. This program is in Phase 1 trials for solid tumors.
- CTX-10726: A newly announced PD-1 x VEGF-A bispecific antibody advancing through preclinical development, with an IND submission expected by year-end 2025.
These candidates reflect Compass’s commitment to addressing high unmet medical needs, particularly in patient populations resistant to existing therapies.
Scientific Excellence and Biomarker-Driven Strategy
Compass Therapeutics integrates biomarker-driven strategies into its clinical development programs. For example, the identification of NCAM (CD56) as a potential biomarker for CTX-471 highlights the company’s ability to leverage cutting-edge science to enhance patient selection and therapeutic efficacy. Similarly, the use of DLL4 as a biomarker in CRC studies underscores Compass’s precision medicine approach.
Collaborative and Industrialized Approach
The company’s “partnership-first” mentality enables it to collaborate with top-tier academic institutions and leverage best-in-class technologies. This decentralized validation model accelerates the transition from discovery to clinical development, ensuring that only the most promising therapeutic combinations advance to human trials.
Competitive Landscape and Market Position
Operating in the highly competitive field of oncology-focused biopharmaceuticals, Compass Therapeutics distinguishes itself through its emphasis on bispecific antibodies and its robust biomarker-driven approach. Competitors include established players like Genentech and Bristol Myers Squibb, but Compass’s focus on immune-oncology and angiogenesis modulation positions it uniquely within the market. The company’s ability to identify and exploit novel biological pathways gives it a competitive edge in addressing complex cancer mechanisms.
Challenges and Opportunities
While Compass Therapeutics faces challenges typical of clinical-stage biopharma companies—such as regulatory hurdles and the inherent risks of drug development—it is well-positioned to overcome these obstacles through its innovative platforms, strong clinical pipeline, and strategic collaborations. The growing emphasis on immuno-oncology and biomarker-driven therapies provides significant opportunities for the company to expand its impact and market presence.
Conclusion
Compass Therapeutics Inc. exemplifies innovation and scientific rigor in the biopharmaceutical industry. With a robust pipeline, proprietary technologies, and a focus on addressing unmet medical needs, the company is poised to make significant contributions to the field of oncology. By targeting critical pathways involved in tumor growth and immune modulation, Compass is advancing the next generation of cancer therapeutics, offering hope to patients worldwide.
Compass Therapeutics (Nasdaq: CMPX) announced a clinical trial collaboration with Merck to evaluate its monoclonal antibody CTX-471 in combination with KEYTRUDA® for treating advanced cancers post anti-PD-1 therapy. The Phase 1b trial will enroll patients with various cancer types and assess safety, pharmacokinetics, and clinical activity. Initial results from earlier trials showed partial responses in patients. This collaboration marks a significant advancement in cancer immunotherapy.
Compass Therapeutics (Nasdaq: CMPX) announced its participation in the 24th Annual H.C. Wainwright Global Investment Conference in New York City, scheduled for September 12 – 14, 2022. The company's presentation is set for September 13, 2022, at 2:30 PM EDT. A webcast of the presentation will be available and archived on their Events page for 90 days.
Compass Therapeutics, Inc. (Nasdaq: CMPX) will present at the 2022 Wedbush PacGrow Healthcare Conference, scheduled virtually for August 9-10, 2022. The presentation is set for August 9 at 4:05 pm ET. Interested parties can access the webcast here, and it will be available for replay for 90 days on Compass’s Events page.
Compass Therapeutics focuses on developing antibody-based therapeutics aimed at treating cancer by targeting critical biological pathways.
Compass Therapeutics (CMPX) reported Q2 2022 results with a net loss of $8.5M ($0.08/share), down from $55.8M ($1.07/share) in Q2 2021. Cash and marketable securities totaled $132M, extending their runway into H2 2024. The company is set to initiate a Phase 2/3 trial for CTX-009 in biliary tract cancer (BTC) and a Phase 2 trial for advanced colorectal cancer (CRC) by Q4 2022. Additionally, CTX-471 continues to show efficacy in mesothelioma patients, with four reported partial responses. R&D expenses rose to $5.9M from $2.9M, while G&A expenses increased to $3.1M from $2.2M, reflecting ongoing operational growth.
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company, will present at the 2022 Jefferies Global Healthcare Conference on June 9, 2022, at 8:00 am ET in New York City. The presentation will focus on the company's proprietary antibody-based cancer therapeutics. It will be available for live streaming and archived for 90 days on their website. Compass Therapeutics aims to advance innovative therapies targeting critical biological pathways in oncology.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-based cancer treatments, announced that CEO Thomas J. Schuetz will present at the 2022 H.C. Wainwright Global Investment Conference from May 23-26, 2022. The webinar will be available on-demand starting May 24, 2022, at 7:00 a.m. ET, and can be accessed through their website. Compass Therapeutics is dedicated to developing therapies targeting angiogenesis and immune response mechanisms to combat tumors, with a pipeline aimed at advancing multiple product candidates.
Compass Therapeutics, Inc. (CMPX) announced the FDA's approval of the investigational new drug application for CTX-009, allowing an expansion to a global Phase 2 study in biliary tract cancer. Interim data indicated a 42% overall response rate (ORR) and a 92% clinical benefit rate (CBR) among the first 24 patients. The CTX-471 Phase 1b study reported 3 partial responses. As of March 31, 2022, the company had $136.4 million in cash, anticipated to fund operations into late 2024, with a reduced net loss of $7.2 million for Q1 2022, compared to $7.3 million in Q1 2021.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-based cancer treatments, announced that CEO Thomas J. Schuetz will present at the Bank of America Securities 2022 Healthcare Conference. The event is set for May 12, 2022, at 11:20 AM PT in Las Vegas. The presentation will be available live and replayed 24 hours post-event on the company's website. Compass is dedicated to developing therapies targeting critical biological pathways essential for effective anti-tumor responses.
Compass Therapeutics (Nasdaq: CMPX) announced interim results from its Phase 2 study of CTX-009, revealing a 42% overall response rate (ORR) based on 10 partial responses among 24 patients with biliary tract cancers. The clinical benefit rate reached 92%, with most patients exhibiting stable disease. The drug was well tolerated, aligning with Phase 1 findings. Compass plans to commence the second stage of the study in the U.S. in Q3 2022. The data suggest CTX-009 may offer a new treatment avenue for patients with limited options.
Compass Therapeutics, Inc. (Nasdaq: CMPX) will host a webinar on May 4, 2022, at 8:00 a.m. ET to discuss clinical data from its ongoing Phase 2 trial of CTX-009. A Key Opinion Leader will join the management for this review. The company focuses on developing proprietary antibody-based therapeutics targeting cancer through a unique approach addressing angiogenesis and immune response. The upcoming session aims to provide insights into trial results, with a replay available for six months on the company's website.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
What does Compass Therapeutics Inc. specialize in?
What are Compass Therapeutics’ key pipeline products?
How does Compass Therapeutics differentiate itself in the oncology market?
What is the significance of biomarkers in Compass’s clinical programs?
What challenges does Compass Therapeutics face?
What is the company’s approach to collaboration?
What are the clinical applications of Tovecimig (CTX-009)?
What is CTX-471, and how does it work?
